Effects of switching from <scp>MiniMed™ 770G</scp> to <scp>780G</scp> on continuous glucose monitoring metrics and <scp>DTR</scp> ‐ <scp>QOL</scp> scores: An observational study of Japanese people with type 1 diabetes mellitus
Switching from the MiniMed™ 770G to the 780G system in Japanese adults with T1D improved both glycemic control and treatment-related QOL, supporting the clinical usefulness of the 780G in real-world clinical practice. This study provides the first one-year real-world evidence of MiniMed™ 780G use in Japan.
Authors
- Fuki Ikeda (ORCID: https://orcid.org/0000-0002-7638-6056)
- Mami Koshibu
- SHOHEI FUJIKAWA
- Tatsuhiro Ayame
- Eri Takagi (ORCID: https://orcid.org/0009-0002-4306-8809)
- Junko Sato
- Yuya Nishida
- Azusa Ozaki
- Haruna Yasuda
- Hirotaka Watada
- Haruki Nagashima
- Ryoki Mori
Institutions
- Juntendo University (JP)
Publication Details
- Journal
- Journal of Diabetes Investigation
- Published
- 2026-02-04
- DOI
- https://doi.org/10.1111/jdi.70257
- Primary Topic
- Diabetes Management and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Eli Lilly and Company
- GlaxoSmithKline
- Sanofi
- Kowa Company
- Boehringer Ingelheim Japan
- Novo Nordisk
- Teijin Pharma
- Mitsubishi Tanabe Pharma Corporation
- Daiichi Sankyo Company
- Daiichi Sankyo Europe